Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs Care Bare Rx

Two GLP-1 desks, one scoreboard. We put Sprout Health and Care Bare Rx head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 38 · Grade C

Care Bare Rx

Visit Care Bare Rx Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 72 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make Care Bare Rx a bad call — it's best for readers who want an oral tirzepatide route or a brand pathway and will complete an intake to learn the cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
72
Supply Reliability
82
80
Transparency
88
52
Access Breadth
92
88
Clinical Oversight
78
70
Track Record
84
72
Sprout HealthBrief Score 86 · 72Care Bare Rx

Price, coverage & the tracker

Sprout HealthCare Bare Rx
Brief Score86/100 (B)72/100 (C)
Semaglutide$149/moFrom $199/mo (shared figure) · brand Ozempic from $705/mo
Tirzepatide$199/moNot separately disclosed
CoverageNot disclosedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

Care Bare Rx: One "$199" covers all weight-loss treatments; per-dose rates stay behind the intake quiz.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.